Clinical Pipeline

Clinical trials for the treatment of HPV-, PSA- and HER2-associated cancers.

Axalimogene filolisbac (ADXS-HPV), Advaxis’s lead drug candidate, is in clinical trials for HPV-associated cancers. In addition, the company has a preclinical program with 20 distinct immunotherapies in development for cancers.

[NOTE: Clinical trials of axalimogene filolisbac are on clinical hold as of Oct. 1, 2015.]

Advaxis Clinical Pipeline

Indication	Phase 1	Phase 2	Phase 3	Trials
Axalimogene filolisbac (ADXS-HPV)
Cervical* AIM2CERV
Cervical* Metastatic Cervical		Phase 2
Cervical* Metastatic - GOG		Phase 2		View Trial
Cervical* Combo with MEDI 47361	Phase 1/2			View Trial
Cervical* Metastatic Single Arm High Dose	Phase 1/2			View Trial
Head and Neck* Neoadjuvant Window of Opportunity - Mount Sinai		Phase 2		View Trial
Head & Neck* Metastatic - Combo with MEDI 47361	Phase 1/2			View Trial
Anal* Adjuvant Single Arm in High Risk - Brown University		Phase 2		View Trial
Anal* Metastatic		Phase 2
ADXS-PSA
Prostate Combo with Keytruda®2	Phase 1/2			View Trial
ADXS-HER2
HER2 Overexpressing Tumors (IND Approved)	Phase 1

Completed

In Progress

Planned

* Orphan Drug Designation Granted

1. Partnership with Medimmune (AZ)
2. Partnership with Merck